Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors
- PMID: 12168829
Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors
Abstract
Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, has been shown to inhibit the development of N-methylnitrosourea (NMU)-induced rat mammary tumors when fed in the diet continuously for the duration of the carcinogenic process. The present study was designed to determine whether the inhibitory effects of SAHA occur during the initiation process or at subsequent stages in the carcinogenic process. In addition, animals with established NMU tumors were administered SAHA to determine whether SAHA could inhibit the continued growth of established mammary tumors. It was found that SAHA fed at 900 ppm in the diet inhibited tumor yields when administered from 14 days prior to NMU administration to termination (-14 to +130) and from +14 and +28 days to termination. However, SAHA had no effect on tumor yields when administered from -14 to +14 or from -14 to +50 days and then returned to the control diets for the remainder of the experimental period (130 days). These results indicate that the inhibitory effects of SAHA are not exerted at the initiation phase of NMU-induced mammary tumorigenesis and appear, instead, to inhibit the subsequent stages in tumor development. Of most interest was the ability of SAHA to inhibit the growth of established mammary tumors. Administration of SAHA in the diet at 900 ppm resulted in significant inhibition of established tumor growth. Thirty-two percent of SAHA-treated tumors exhibited partial regression compared to 12% of controls, growth was stabilized in 24% of treated tumors compared to 12% of controls while 11% exhibited complete regression compared to 0% of controls. Collectively, SAHA-treated tumors exhibited a 7-fold reduction in growth compared to untreated tumors over the test period. The results of this animal model study indicate that SAHA, when fed in the diet, serves as both a chemopreventive and chemotherapeutic agent in the absence of any detectable side effects.
Similar articles
-
Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA).Anticancer Res. 1999 Nov-Dec;19(6B):4999-5005. Anticancer Res. 1999. PMID: 10697502
-
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.Cancer Res. 2000 Sep 15;60(18):5165-70. Cancer Res. 2000. PMID: 11016644
-
LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model.Cancer Res. 2001 Dec 15;61(24):8683-8. Cancer Res. 2001. PMID: 11751385
-
Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.Blood Cells Mol Dis. 2001 Jan-Feb;27(1):260-4. doi: 10.1006/bcmd.2000.0376. Blood Cells Mol Dis. 2001. PMID: 11358386 Review. No abstract available.
-
Mammary tumor inhibition by IP6: a review.Anticancer Res. 1999 Sep-Oct;19(5A):3671-4. Anticancer Res. 1999. PMID: 10625937 Review.
Cited by
-
Medical management of metastatic medullary thyroid cancer.Cancer. 2014 Nov 1;120(21):3287-301. doi: 10.1002/cncr.28858. Epub 2014 Jun 18. Cancer. 2014. PMID: 24942936 Free PMC article. Review.
-
Identification of druggable genes for multiple myeloma based on genomic information.Genomics Inform. 2023 Sep;21(3):e31. doi: 10.5808/gi.23011. Epub 2023 Sep 27. Genomics Inform. 2023. PMID: 37813627 Free PMC article.
-
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.Invest New Drugs. 2008 Feb;26(1):81-7. doi: 10.1007/s10637-007-9075-2. Epub 2007 Oct 25. Invest New Drugs. 2008. PMID: 17960324 Clinical Trial.
-
Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21WAF1/CIP1 and p27KIP1 in Cancer Cells.Medicina (Kaunas). 2019 Jan 29;55(2):30. doi: 10.3390/medicina55020030. Medicina (Kaunas). 2019. PMID: 30700046 Free PMC article.
-
Chemoprevention of mouse lung and colon tumors by suberoylanilide hydroxamic acid and atorvastatin.Int J Cancer. 2012 Sep 15;131(6):1277-86. doi: 10.1002/ijc.27395. Epub 2012 Jan 31. Int J Cancer. 2012. PMID: 22161747 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources